Patients who had been diagnosed with advanced disease of pancreatic cancer receiving targeted therapy alongside other treatment had been reported with an average of one extra year of survival than those who received standard chemotherapy(survival-31 vs 18 months). Read more . . .
Pancreatic cancer is an intractable disease that often evades early diagnosis and defies treatment. Targeted therapy for pancreatic cancer patients may give an extra year of survival, showed by an observational study conducted at the University of Texas MD Anderson Cancer Centre, USA, published in The Lancet Oncology journal.